Predmide-P (prednisolone + sulphacetamide + phenylephrine): Uses, Dosage & Side Effects

What it's for (Indications)

Prednisolone + Sulphacetamide + Phenylephrine ophthalmic drops are indicated for steroid-responsive inflammatory ocular conditions where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.
This includes chronic anterior uveitis, ocular injury from chemical, radiation, or thermal burns, or penetration of foreign bodies.
It is also used in cases of allergic conjunctivitis, blepharitis, and other inflammatory conditions of the conjunctiva, cornea, and anterior segment of the globe that are responsive to corticosteroids.
The combination aims to reduce inflammation while providing prophylaxis or treatment against susceptible bacterial pathogens, often employed in post-operative settings to manage both inflammation and potential infection.

Dosage Information

Type	Guideline
Standard	The typical dosage involves instilling one or two drops into the conjunctival sac of the affected eye(s) two to four times daily. In severe cases, the frequency of administration may be increased during the initial 24 to 48 hours to up to every hour, but caution should be exercised. Following this initial intense therapy, the frequency should be gradually tapered as the condition improves to avoid potential adverse effects and rebound inflammation. The duration of treatment should be determined by an ophthalmologist based on the patient's clinical response and should generally be as short as possible to minimize the risk of corticosteroid-associated complications. It is crucial for patients to strictly adhere to the prescribed regimen and not discontinue treatment abruptly without medical advice.

Type

Guideline

Standard

The typical dosage involves instilling one or two drops into the conjunctival sac of the affected eye(s) two to four times daily. In severe cases, the frequency of administration may be increased during the initial 24 to 48 hours to up to every hour, but caution should be exercised. Following this initial intense therapy, the frequency should be gradually tapered as the condition improves to avoid potential adverse effects and rebound inflammation. The duration of treatment should be determined by an ophthalmologist based on the patient's clinical response and should generally be as short as possible to minimize the risk of corticosteroid-associated complications. It is crucial for patients to strictly adhere to the prescribed regimen and not discontinue treatment abruptly without medical advice.

Safety & Warnings

Common Side Effects

Common ocular side effects include transient stinging or burning upon instillation, blurred vision, ocular irritation, and conjunctival hyperemia (redness).
Prolonged use of the corticosteroid component (prednisolone) can lead to significant and serious ocular adverse events such as increased intraocular pressure (IOP) potentially resulting in glaucoma with optic nerve damage, defects in visual acuity and fields, and posterior subcapsular cataract formation.
Secondary ocular infections (bacterial, fungal, viral) may also occur or be masked.
Other potential corticosteroid-related effects include delayed wound healing, and in conditions causing thinning of the cornea or sclera, the risk of perforation is increased.
The sulphacetamide component may cause localized hypersensitivity reactions, including angioedema, urticaria, and photodermatitis, and rarely, severe systemic reactions like Stevens-Johnson syndrome or toxic epidermal necrolysis.
Phenylephrine can cause pupillary dilation (mydriasis), which may precipitate acute angle-closure glaucoma in predisposed individuals, and rebound conjunctival hyperemia.
Systemic absorption of phenylephrine can lead to cardiovascular effects such as increased blood pressure and heart rate, especially in susceptible individuals or with excessive use.

Serious Warnings

Black Box Warning: While this specific combination ophthalmic product (Prednisolone + Sulphacetamide + Phenylephrine) does not typically carry a formal FDA Black Box Warning, several serious safety concerns warrant prominent attention for healthcare professionals and patients: **Serious Warnings: 1. **Risk of Glaucoma and Optic Nerve Damage**: Prolonged use of ophthalmic corticosteroids, even at standard doses, is associated with a significant risk of increased intraocular pressure (IOP) and the development of glaucoma, potentially leading to irreversible damage to the optic nerve, and permanent defects in visual acuity and visual fields. Regular and frequent monitoring of IOP is imperative for any patient receiving extended corticosteroid therapy. 2. **Cataract Formation**: Posterior subcapsular cataract formation has been unequivocally linked to the prolonged use of ophthalmic corticosteroids. 3. **Exacerbation or Masking of Ocular Infections**: The corticosteroid component of this medication can suppress the host immune response, thereby increasing the risk of secondary ocular infections (bacterial, fungal, or viral) or exacerbating existing ones. Fungal infection should be strongly suspected in any persistent corneal ulceration where corticosteroid use has occurred. The antibiotic component is effective only against susceptible bacterial infections and offers no protection against fungal or viral pathogens. 4. **Hypersensitivity Reactions (Sulfonamides)**: Although rare with topical ophthalmic administration, severe, potentially fatal hypersensitivity reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias) have been associated with systemic sulfonamide administration. Patients should be advised to discontinue treatment at the first sign of a serious adverse reaction (e.g., skin rash, persistent redness, or swelling) and seek immediate medical attention.
This combination drug carries several critical warnings.
Prolonged use of ophthalmic corticosteroids can lead to elevated intraocular pressure (IOP) and glaucoma, with potential for damage to the optic nerve and visual field defects; regular monitoring of IOP is essential.
Posterior subcapsular cataract formation has also been associated with extended corticosteroid therapy.
The corticosteroid component can mask, enhance, or exacerbate existing bacterial, fungal, or viral ocular infections, necessitating careful diagnosis and monitoring.
Any persistent corneal ulceration where a corticosteroid has been used should prompt suspicion of fungal infection.
In patients with conditions causing thinning of the cornea or sclera, the use of topical corticosteroids may lead to perforation.
Sulfonamides, like sulphacetamide, can cause severe, although rare, systemic hypersensitivity reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and blood dyscrasias, even with topical ophthalmic administration.
Phenylephrine should be used with caution in patients with hypertension, cardiac disease, or hyperthyroidism due to potential systemic absorption and associated cardiovascular effects.
Pupillary dilation caused by phenylephrine may precipitate acute angle-closure glaucoma in individuals with narrow anterior chamber angles.
Contact lenses should be removed prior to instillation and not reinserted for at least 15 minutes.
Prolonged use of the antibiotic component may result in the overgrowth of non-susceptible organisms, including fungi, necessitating appropriate evaluation and management.

How it Works (Mechanism of Action)

The therapeutic effect of this ophthalmic combination is derived from the synergistic actions of its three active components. Prednisolone acetate is a potent synthetic glucocorticoid that exerts significant anti-inflammatory and immunosuppressive effects. It functions by diffusing into target cells, binding to specific cytoplasmic glucocorticoid receptors, and subsequently modulating gene expression. This process leads to the synthesis of anti-inflammatory proteins (e.g., lipocortins) and the inhibition of pro-inflammatory mediators such as prostaglandins, leukotrienes, and various cytokines, thereby reducing ocular swelling, redness, and pain. Sulphacetamide sodium is a bacteriostatic sulfonamide antibiotic. Its mechanism involves competitive inhibition of para-aminobenzoic acid (PABA), a crucial precursor for bacterial folic acid synthesis. By blocking this essential metabolic pathway, sulphacetamide prevents the growth and replication of susceptible bacteria in the eye. Phenylephrine hydrochloride is a direct-acting sympathomimetic amine primarily acting as an alpha-1 adrenergic receptor agonist. In the ocular context, it induces vasoconstriction of the conjunctival blood vessels, leading to effective ocular decongestion and a reduction in conjunctival redness. Additionally, it causes pupillary dilation (mydriasis) by stimulating the alpha-receptors in the iris dilator muscle.